Notifiable Share Interest in Maxygen, Inc.
GlaxoSmithKline plc ("GSK") announces that on 30 December 2009 GSK sold 5,121,488 Common shares of Maxygen, Inc. ("Maxygen"), a biopharmaceutical company focused on developing improved versions of protein drugs, located in the United States and whose shares are traded on the NASDAQ Exchange.
GSK's interest, which is held by Glaxo Group Limited and GlaxoSmithKline Services Unlimited, now comprises 1,433,361 shares or 4.47% of Maxygen. The calculation is based on a total of 32,041,239 shares outstanding in Maxygen. This decreased interest is as a result of a tender offer by Maxygen to repurchase shares, and is disclosable under the rules of the United States Securities Exchange Act of 1934.
Simon M Bicknell
Company Secretary
4 January 2010